For example, such targeted small-molecule drugs as Janus Kinase Inhibitors(JAKs), Bruton Tyrosine Kinase (BTK), Spleen Tyrosine Kinase(SYK), and Sphingosine 1-Phosphate Receptor(Sphingosine 1-Phosphate Receptor) are being developed for the treatment of malignant and autoimmune diseases, including SLE [5]. This evidence concerns the gene BTK and autoimmune disease.